DeepMed Research

UCB BIOPHARMA SRL

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Subsidiary

Employees: -

Market Cap: -

Website

Clinical Trials

A Study to Assess the Safety and Tolerability, and Pharmacokinetics of UCB0022 in Healthy Caucasian, Japanese, and Chinese Participants

Phase 1

Recruiting

Conditions: Healthy Study Participants

Interventions: Drug: glovadalen
Other: Placebo

First Posted Date: 2025-05-14

Last Posted Date: 2025-05-14

Lead Sponsor: UCB Biopharma SRL

Target Recruit Count: 32

Registration Number: NCT06970301

Locations: 🇺🇸
Up0135 1001, Glendale, California, United States

A Study to Assess Zilucoplan Concentration in Breast Milk of Healthy Lactating Women

Phase 1

Not yet recruiting

Conditions: Healthy Participants

Interventions: Drug: Zilucoplan

First Posted Date: 2025-05-08

Last Posted Date: 2025-05-08

Lead Sponsor: UCB Biopharma SRL

Target Recruit Count: 15

Registration Number: NCT06961747

A Study to Assess the Pharmacokinetics and Safety of Bimekizumab in Children and Adolescents With Moderate to Severe Hidradenitis Suppurativa

Phase 3

Recruiting

Conditions: Hidradenitis Suppurativa

Interventions: Drug: Bimekizumab

First Posted Date: 2025-04-10

Last Posted Date: 2025-05-11

Lead Sponsor: UCB Biopharma SRL

Target Recruit Count: 40

Registration Number: NCT06921850

Locations: 🇺🇸
Hs0006 50712, Bowling Green, Kentucky, United States
🇺🇸
Hs0006 50708, Roseville, California, United States
🇺🇸
Hs0006 50178, Clarkston, Michigan, United States

and more 3 locations

A Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® (Bimekizumab)

Phase 1

Recruiting

Conditions: Moderate to Severe Plaque Psoriasis
Psoriatic Arthritis
Axial Spondyloarthritis
Hidradenitis Suppurativa

Interventions: Drug: Bimekizumab

First Posted Date: 2025-03-21

Last Posted Date: 2025-05-21

Lead Sponsor: UCB Biopharma SRL

Target Recruit Count: 20

Registration Number: NCT06888193

Locations: 🇨🇦
Up0122 202, Calgary, Canada

A Study to Assess the Concentration of Rozanolixizumab in the Breast Milk of Healthy Lactating Women

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: Rozanolixizumab

First Posted Date: 2024-12-06

Last Posted Date: 2025-05-20

Lead Sponsor: UCB Biopharma SRL

Target Recruit Count: 15

Registration Number: NCT06720714

Locations: 🇺🇸
UP0141 2, San Antonio, Texas, United States
🇺🇸
UP0141 1, Salt Lake City, Utah, United States

A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of a Single Dose of Donzakimig in Healthy Chinese and Japanese Participants

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: Donzakimig
Drug: Placebo

First Posted Date: 2024-12-04

Last Posted Date: 2025-04-15

Lead Sponsor: UCB Biopharma SRL

Target Recruit Count: 32

Registration Number: NCT06716879

Locations: 🇺🇸
UP0142 1, Anaheim, California, United States

An Open-label Study to Evaluate the Pharmacokinetics and Safety of Bimekizumab in Pediatric Study Participants With Active Juvenile Idiopathic Arthritis Subtypes Enthesitis-related Arthritis (Including Juvenile-onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis

Phase 3

Recruiting

Conditions: Enthesitis-related Arthritis
Juvenile Psoriatic Arthritis

Interventions: Drug: Bimekizumab

First Posted Date: 2024-10-31

Last Posted Date: 2025-05-11

Lead Sponsor: UCB Biopharma SRL

Target Recruit Count: 40

Registration Number: NCT06668181

Locations: 🇨🇦
Ja0005 50645, Saskatoon, Canada
🇩🇪
Ja0005 40779, Sendenhorst, Germany
🇨🇦
Ja0005 50646, Calgary, Canada

and more 9 locations

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants With Active Psoriatic Arthritis

Phase 3

Recruiting

Conditions: Psoriatic Arthritis

Interventions: Drug: Bimekizumab
Drug: Risankizumab
Drug: Placebo

First Posted Date: 2024-10-02

Last Posted Date: 2025-05-11

Lead Sponsor: UCB Biopharma SRL

Target Recruit Count: 550

Registration Number: NCT06624228

Locations: 🇩🇪
Pa0016 40073, Bad Nauheim, Germany
🇪🇸
Pa0016 40269, Bilbao, Spain
🇩🇪
Pa0016 40138, Bonn, Germany

and more 115 locations

A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus

Phase 3

Recruiting

Conditions: Systemic Lupus Erythematosus

Interventions: Drug: DZP
Other: Placebo

First Posted Date: 2024-09-27

Last Posted Date: 2025-05-16

Lead Sponsor: UCB Biopharma SRL

Target Recruit Count: 450

Registration Number: NCT06617325

Locations: 🇨🇳
Sl0044 20099, Taipei City, Taiwan
🇨🇳
Sl0044 20082, Taiyuan CITY, Taiwan
🇩🇪
Sl0044 40078, Leipzig, Germany

and more 129 locations

A First-in-human Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of UCB3101 in Healthy Participants

Phase 1

Recruiting

Conditions: Healthy Participants

Interventions: Drug: UCB3101
Drug: Placebo

First Posted Date: 2024-08-15

Last Posted Date: 2025-04-11

Lead Sponsor: UCB Biopharma SRL

Target Recruit Count: 64

Registration Number: NCT06555601

Locations: 🇧🇪
UP0124 1, Edegem, Belgium

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy